Trial Profile
A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study in Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms inTandem4
- Sponsors Lexicon Pharmaceuticals
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 01 Aug 2017 According to a Lexicon Pharmaceuticals media release, data will be presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon.
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association